PAUL NEWTON, Centre for Clinical Vaccinology and Tropical Medicine, Oxford REFERENCE: Lancet Infect Dis 2006; 6:602-13 No one knows the exact proportion of anti-infective drugs in the developing world
PAUL NEWTON, Centre for Clinical Vaccinology and Tropical Medicine, Oxford
REFERENCE: Lancet Infect Dis 2006; 6:602-13
No one knows the exact proportion of anti-infective drugs in the developing world which are not genuine, but even a conservative estimate tells us that counterfeit drugs affect millions of people. A review in the Lancet Infectious Diseases has tried to bring together the available data and propose some solutions to the problem, and Derek Thorne found out more fromPaul Newton, of the Centre for Clinical Vaccinology and Tropical Medicine in Oxford.
Related Episodes
Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability
Peter Tyrer REFERENCE: Lancet 371:57 January 5, 2008 PETER TYRER, Imperial College, W6 8RP London A randomized study comparing treatment with risperidone, or haloperidol, or placebo to treat patients
New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
Jose Baselga JOSE BASELGA, Vall d’Hebron Hospital, Barcelona RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The in
New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura
Terry Gernsheimer TERRY GERNSHEIMER, University of Washington Medical Center, Seattle An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chroni